GLENMARK — Glenmark Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Glenmark Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	R2019 March 31st	2020 March 31st	2021 March 31st	2022 March 31st	R2023 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Interim Report	ARS	ARS	ARS	Interim Report
Standards:	—	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	98,655	106,410	109,439	123,049	115,832
Cost of Revenue
Gross Profit	59,362	64,322	66,167	73,261	73,257
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	84,384	93,260	92,586	107,258	112,833
Operating Profit	14,271	13,150	16,854	15,791	3,000
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	13,006	10,961	13,825	14,412	2,398
Provision for Income Taxes
Net Income After Taxes	9,250	7,760	9,701	9,936	-896
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	9,250	7,760	9,701	9,417	2,972
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	9,250	7,760	9,701	9,417	2,972
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	28.6	26.7	33.3	39.9	11.6
Dividends per Share